. 2016 Jan 20;9:421–429. doi: 10.2147/OTT.S72845

Table 4.

Ongoing studies with ofatumumab single agent or in combination in CLL

Study	Phase	Treatment	n	ORR (%)	Median PFS, months	Median OS, months
van Oers et al⁴⁰	III	Maintenance Ofa vs observation in relapsed patients after salvage therapy	474	Time to next therapy 38 vs 27.4 months	28.6 vs 15.2	No differences in OS at the interim analysis
Robak et al⁴¹	III	Ofa plus FC vs FC alone in relapsed patients	365
Robak et al⁴¹	III	Ofa plus FC vs FC alone in relapsed patients	183 vs 182	84 vs 68	28.9 vs 18.8	56.4 vs 45.8
Jones et al⁴²	III	Ofa plus Idela vs Ofa in relapsed patients	261
Jones et al⁴²	III	Ofa plus Idela vs Ofa in relapsed patients	174 vs 87	75 vs 18	16.3 vs 8.0	20.9 vs 19.4

Abbreviations: CLL, chronic lymphocytic leukemia; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; Ofa, ofatumumab; FC, fludarabine + cyclophosphamide; Idela, idelalisib.